ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 767

Hydroxychloroquine Induced Retinopathy in SLE

Michelle Petri1 and Wei Fu2, 1Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: eye disease and hydroxychloroquine, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Retinal toxicity from hydroxychloroquine (HCQ), has been recognized for many years. But poor compliance of HCQ might confound results of previous studies. Therefore, we tried to understand HCQ induced retinopathy by investigating association between retinopathy and HCQ serum level.

Methods: 117 patients with HCQ toxicity report and HCQ level measured were included in the analysis. Patients were then followed quarterly since cohort entry. HCQ level were measured at each visit and patients taking HCQ were referred to Ophthalmologists for eye exams.

Results: Among 117 patients, 112 (95.7%) were female. Majority (49.6%) were Caucasian, 44.4% African American. 12 of them have HCQ toxicity confirmed while 7 were possible and majority (83.8%) don’t have HCQ toxicity. Table 1 showed HCQ toxicity in each HCQ group. Table 1: HCQ toxicity in each HCQ group

Highest HCQ level (ng/mL) No toxicity N (%) Possible Toxicity N (%) confirmed toxicity N (%) Total
Greater than 2,000 25 (83.3) 2 (6.7) 3 (10.0) 30
1,500 to 1,999 23 (79.3) 4 (13.8) 2 (6.9) 29
1,000 to 1,499 30 (85.7) 1 (2.9) 4 (11.4) 35
500 to 999 13 (100) 0 (0) 0 (0) 13
Less than 499 7 (70.0) 0 (0) 3 (30.0) 10

Pair-wise comparison using t test with pooled Standard deviation showed that average highest HCQ levels are not significantly different among three groups (No vs. possible vs. Yes) After grouping people with “confirmed” toxicity and “possible” toxicity together, average highest HCQ level is 1511.632 ng/mL. While highest HCQ level is 1591.051 ng/mL on average among those who didn’t show HCQ toxicity. The difference between these two groups is not significant (P = 0.7094) using t test.

Conclusion: Retinopathy is not associated with highest HCQ level.


Disclosure: M. Petri, None; W. Fu, None.

To cite this abstract in AMA style:

Petri M, Fu W. Hydroxychloroquine Induced Retinopathy in SLE [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/hydroxychloroquine-induced-retinopathy-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hydroxychloroquine-induced-retinopathy-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology